Oncology Corporate Profile
Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|BLU-285®||PDGFR®D842V inhibitor||Gastrointestinal Stromal Tumors (GIST)||I|
|BLU-554||PDGFR®D842V inhibitor||Hepatocellular carcinoma (HCC)||I|
|BLU-667||RET inhibitor||Non Small Cell Lung Cancer (NSCLC)||I|
|BLU-667||RET inhibitor||Thyroid cancer||I|
3/30/2017 08:04 pm